News AstraZeneca PLC

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 06:36:17 2024-05-07 am EDT			5-day change	1st Jan Change
12,097 ^GBX	+0.39%		+0.18%	+14.00%

09:00am	BP starts USD1.75 billion share buyback scheme	AN
May. 06	Cellectis: alliance with AstraZeneca finalized	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BP starts USD1.75 billion share buyback scheme	03:00am	AN
ANGLE PLC - NEW COMMERCIAL AGREEMENT WITH LARGE PHARMA	May. 06	AQ
Cellectis: alliance with AstraZeneca finalized	May. 06	CF
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	May. 06	MT
AstraZeneca: equity investment in Cellectis	May. 06	CF
AstraZeneca completes collaboration and investment deal with Cellectis	May. 06	AN
AstraZeneca Secures 44% Stake in French Biotech Cellectis	May. 06	MT
Combination treatment could provide new standard-of-care for aggressive lymphoma	May. 03	AQ
AI Startup Fileread Names Former AstraZeneca Legal Leader as Chief Strategy Officer and General Counsel to Drive Product Development and Accelerate Growth	May. 03	AQ
Angle shares up on assay development deal with AstraZeneca	May. 03	AN
Astrazeneca - CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 03	AQ
Angle shares up on assay development deal with AstraZenaca	May. 03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	May. 03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	May. 03	AN
Confident start before US jobs data	May. 03	AN
InterContinental Hotels makes first-quarter progress	May. 03	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	May. 02	MT
AstraZeneca: research into respiratory diseases	May. 02	CF
AstraZeneca : Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial - Form 6-K	May. 02	PU
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial	May. 02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT